Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?

Area of Science:

• Urology
• Endocrinology
• Men's Health

Background:

• Traditional understanding linked prostatic growth directly to testosterone levels.
• Emerging evidence suggests a potential role for testosterone deficiency in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).

Purpose of the Study:

• To review the current understanding of hypogonadism's physiology.
• To explore the interplay between hypogonadism and prostatic/lower urinary tract physiology.
• To evaluate the impact of testosterone replacement therapy (TRT) on LUTS/BPH.

Main Methods:

• Literature review of existing research on hypogonadism, LUTS, and BPH.
• Analysis of physiological mechanisms linking testosterone levels to prostate and bladder function.
• Examination of clinical evidence regarding TRT in hypogonadal men with LUTS/BPH.

Main Results:

• Hypogonadism, or low testosterone, is identified as a significant risk factor for developing LUTS and BPH.
• Testosterone replacement therapy (TRT) was found not to exacerbate LUTS in hypogonadal individuals.
• The study challenges the long-held belief that high testosterone levels directly cause prostate issues.

Conclusions:

• Hypogonadism is an important risk factor for LUTS/BPH, contrary to previous assumptions.
• Testosterone replacement therapy is safe and potentially beneficial for hypogonadal men experiencing LUTS/BPH.
• Revisiting the role of testosterone in prostate health is crucial for understanding and managing LUTS/BPH.